Brief: Paion: China's NMPA Grants Market Approval For Remimazolam For Use In Procedural Sedation
20/07/2020 15:31
July 20 (Reuters) - PAION AG PA8G.DE :
* NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA) IN CHINA
GRANTS
MARKET APPROVAL FOR REMIMAZOLAM FOR USE IN PROCEDURAL SEDATION
IN CHINA
Source text for Eikon: ID:nEQ7sR34Qa
Further company coverage: PA8G.DE
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on PAION AG
See all newsBrief: Paion AG To Issue Approx 4.8 Mln Shares In Capital Increase With Subscription Rights
Brief: Paion AG Reports Developments On Commercial Activities In Europe
Brief: Paion Q1 EBITDA Up At EUR 15 Mln
Brief: Paion Grants Exclusive License To Cristália For Development And Commercialization Of Remimazolam In Latin America
Brief: Paion Announces Sebastian Werner As New CFO, Effective 1 June 2022